Skip to main content Accessibility help
×
Home
  • Print publication year: 2013
  • Online publication date: August 2013

Chapter 14 - Psychosis

from Section 3 - Specific neuropsychiatric disorders

References

1. FénelonG, MahieuxF, HulonR, ZiéglerM.Hallucinations in Parkinson's disease: prevalence, phenomenology, and risk factors. Brain 2000; 123: 733–45.
2. HelyMA, MorrisJG, ReidWG, TrafficanteR.Sydney multicenter study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005; 20: 190–9.
3. MackJ, RabinsP, AndersonK, et al. Prevalence of psychotic symptoms in a community-based parkinson disease sample. Am J Geriatr Psychiatry 2012; 20: 123–32.
4. ForsaaEB, LarsenJP, Wentzel-LarsenT, et al. A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol 2010; 67: 996–1001.
5. LeeAH, WeintraubD.Psychosis in Parkinson's disease without dementia: common and comorbid with other non-motor symptoms. Mov Disord 2012; 27: 858–63.
6. HelyMA, ReidWG, AdenaMA, HallidayGM, MorrisJG.The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008; 23: 837–44.
7. GoetzC, StebbinsG.Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 1993; 43: 2227–9.
8. Sanchez-RamosJ, OrtollR, PaulsonG.Visual hallucinations associated with Parkinson's disease. Arch Neurol Psychiatry 1996; 53: 1265–8.
9. KlawansH.Levodopa-induced psychosis. Psychiatry Ann 1978; 8: 447–71.
10. FénelonG, MahieuxF, HuonR, ZieglerM.Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 2000; 123: 733–45.
11. BarnesJ, DavidA.Visual hallucination in Parkinson's disease: a review and phenomenological survey. J Neurol Neurosurg Psychiatry 2001; 70: 727–33.
12. HolroydS, CurrieL, WootenGF.Prospective study of hallucinations and delusions in Parkinson's disease. J Neurol Neurosurg Psychiatry 2001; 70: 734–8.
13. GiladiN, TrevesTA, PaleacuD, et al. Risk factors for dementia, depression, and psychosis in long-standing Parkinson's disease. J Neural Transm 2000; 107: 59–71.
14. RavinaB, MarderK, FernandezHH, et al. Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS/ NIMH work group. Mov Disord 2007; 22: 1061–8.
15. MarshL, WilliamsJR, RoccoM, et al. Psychiatric comorbidities in patients with Parkinson disease and psychosis. Neurology 2004; 63: 293–300.
16. InzelbergR, KipervasserS, KorczynAD.Auditory hallucinations in Parkinson's disease. J Neurol Neurosurg Psychiatry 1998; 64: 533–5.
17. FactorSA, MolhoES.Threatening auditory hallucinations and Cotard syndrome in Parkinson disease. Clin Neuropharmacol 2004; 27: 205–7.
18. MarshL.Psychosis in Parkinson's Disease. Curr Treat Option Neurol 2004; 6: 181–9.
19. SollaP, CannasA, FlorisGL, Behavioral, neuropsychiatric and cognitive disorders in Parkinson's disease patients with and without motor complications. Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jun 1; 35: 1009–13.
20. KiziltanG, OzekmekciS, ErtanS, et al. Relationship between age and subtypes of psychotic symptoms in Parkinson's disease. J Neurol 2007; 254: 448–52.
21. WilliamsDR, LeesAJ.Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study. Lancet Neurol 2005; 4: 605–10.
22. McKeithIG, DicksonDW, LoweJ, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65: 1863–72.
23. DicksonDW, BraakH, DudaJE, et al. Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol 2009; 8: 1150–7.
24. UchiyamaM, NishioY, YokoiK, et al. Pareidolias: complex visual illusions in dementia with Lewy bodies. Brain 2012; 135: 2458–69.
25. AarslandD, PerryR, LarsenJP, et al. Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias. J Clin Psychiatry 2005; 66: 633–7.
26. FernandezHH, AarslandD, FénelonG, et al. Scales to assess psychosis in Parkinson's disease: critique and recommendations. Mov Disord 2008; 23: 484–500.
27. FactorSA, SteenlandNK, HigginsDS, et al. Disease-related and genetic correlates of psychotic symptoms in Parkinson's disease. Mov Disord 2011; 26: 2190–5.
28. AarslandD, BrønnickK, EhrtU, et al. Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry 2007; 78: 36–42.
29. PacchettiC, ManniR, ZangagliaR, et al. Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson's disease. Mov Disord 2005; 20: 1439–48.
30. MoskovitzC, MosesH, KlawansHL.Levodopa-induced psychosis: a kindling phenomenon. Am J Psychiatry 1978; 135: 669–75.
31. PappertEJ, GoetzCG, NiedermanFG, et al. Sleep fragmentation, and altered dream phenomena in PD. Mov Disord 1999; 14: 117–21.
32. GoetzC, WuuJ, CurgianLM, LeurgansS.Hallucinations and sleep disorders in PD: six-year prospective longitudinal study. Neurology 2005; 6: 81–6.
33. LavaultS, Leu-SemenescuS, Tezenas duMS, et al. Does clinical rapid eye movements behavior disorder predict worse outcomes in Parkinson's disease?J Neurol 2010; 257: 1154–9.
34. PostumaRB, GagnonJF, VendetteM, CharlandK, MontplaisirJ.Mov Disord 2008; 23: 1665–72.
35. ManfordM, AndermannF.Complex visual hallucinations: clinical and neurobiological insights. Brain 1998; 121: 1819–40.
36. BallangerB, StrafellaAP, van EimerenT, et al. Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch Neurol 2010; 67: 416–21.
37. BallardC, PiggottM, JohnsonM, et al. Delusions associated with elevated muscarinic binding in dementia with Lewy bodies. Ann Neurol 2000; 48: 868–76.
38. JanzenJ, van't EntD, LemstraAW, et al. The pedunculopontine nucleus is related to visual hallucinations in Parkinson's disease: preliminary results of a voxel-based morphometry study. J Neurol 2012; 259: 147–54.
39. Ibarretxe-BilbaoN, JunqueC, MartiMJ, TolosaE.Cerebral basis of visual hallucinations in Parkinson's disease: structural and functional MRI studies. J Neurol Sci 2011; 310: 79–81.
40. KlawansHL, GoetzC, NausiedaPA, WeinerWJ.Levodopa-induced dopamine receptor hypersensitivity. Trans Am Neurol Assoc 1977; 102: 80–3.
41. Van der MastFC, FekkesD.Serotonin and aminoacids: partners in delirium pathophysiology?Semin Clin Neuropsychiatry 2000; 5: 125–31.
42. ZoldanJ, FriedbergG, LivnehM, MelamedE.Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology 1995; 45: 1305–8.
43. ChouKL, FernandezHH.Combating psychosis in patients with Parkinson's disease patients: the use of antipsychotic drugs. Expert Opin Investig Drugs 2006; 15: 339–49.
44. FeldmanRG, LannonMC.Parkinson disease: individualizing therapy. Hosp Pract (Off Ed) 1985; 20: 80A–80E, 80I, 80M.
45. ZahodneL, FernandezHH.Pathophysiology and treatment of psychosis in Parkinson's disease. Drugs Aging 2008; 25: 665–82.
46. FernandezHH, TrieschmannME, BurkeMA, FriedmanJH.Quetiapine use for psychosis in Parkinson's disease versus dementia with Lewy bodies. J Clin Psychiatry 2002; 63: 513–15.
47. FernandezHH, TrieschmannME, FriedmanJH.The treatment of psychosis in Parkinson's disease: safety and considerations. Drug Safety 2003; 26: 643–59.
48. FernandezHH, DonnellyEM, FriedmanJH.Long-term outcome of clozapine use for psychosis in Parkinson's patients. Mov Disord 2004; 19: 831–3.
49. SinghS, WooltortonE.Increased mortality among elderly patients with dementia using atypical antipsychotics. CMAJ 2005; 173: 252.
50. MiyasakiJM, ShannonK, VoonV, et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66: 996–1002.
51. RomrellJ, FernandezHH, OkunMS.Rationale for current therapies in Parkinson's disease. Expert Opin Pharmacother 2003; 4: 1747–61.
52. FernandezHH, McCownKM, RomrellJ, et al. New-onset diabetes mellitus among Parkinsonian patients treated with long-term quetiapine. Drug Target Insights 2008; 3: 27–9.
53. FernandezHH, FriedmanJH, LansangMC, et al. Diabetes mellitus among parkinsonian patients treated chronically with clozapine. Parkinsonism Relat Disord. 2004; 10: 439–41.
54. MarrasC, GruneirA, WangX, et al. Antipsychotics and mortality in parkinsonism. Am J Geriatr Psychiatry 2012; 20: 149–58.
55. SchneiderLS, DagermanKS, InselP.Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294: 1934–43.
56. Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 1999; 340: 757–63.
57. FactorSA, FriedmanJH, LannonMC.Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: results of the 12 week open label extension in the PSYCLOPS trial. Parkinson Study Group. Mov Disord 2001; 16: 135–9.
58. KleinC, ProkhorovT, MiniovichA, DobronevskyE, RabeyJM.Long-term follow-up (24 months) of quetiapine treatment in drug-induced Parkinson disease psychosis. Clin Neuropharmacol 2006; 29: 215–19.
59. MecoG, AlessandriaA, BonifatiV, et al. Risperidone for hallucinations in levodopa-treated Parkinson's disease patients. Lancet 1994; 343: 1370–1.
60. WorkmanRH, OrengoCA, BakeyAA, et al. The use of risperidone for psychosis and agitation in demented patients with Parkinson's disease. J Neuropsychiatry Clin Neurosci 1997; 9: 594–7.
61. MohrE, MendisT, HildebrandK, et al. Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: an open pilot trial. Mov Disord 2000; 15: 1230–7.
62. ConnemannBJ, Schonfeldt-LecuonaC.Ziprasidone in Parkinson's disease psychosis. Can J Psychiatry 2004; 49: 73.
63. ShiahIS, LinCL, MaoWC, et al. Ziprasidone in the treatment of Parkinson's disease psychosis. Eur Psychiatry 2006; 21: 578–9.
64. FernandezHH, TrieschmannME, FriedmanJH.Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience. Clin Neuropharmacol 2004; 27: 4–5.
65. FriedmanJH, BermanRM, GoetzCG, et al. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Mov Disord 2006; 21: 2078–81.
66. WeintraubD, ChenP, IgnacioRV, et al. Patterns and trends in antipsychotic prescribing for Parkinson disease psychosis. Arch Neurol 2011; 68: 899–904.
67. AbbasA, RothBL.Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders. Expert Opin Pharmacother 2008; 9: 3251–9.
68. MeltzerHY, MillsR, RevellS, et al. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of Parkinson's disease psychosis. Neuropsychopharmacology 2010; 35: 881–92.
69. YadavPN, KroezeW, FarrellM, RothBL.Antagonist functional selectivity: 5-HT2A serotonin receptor antagonists differentially regulate 5-HT2A receptor protein level in vivo. J Pharmacol Exp Ther 2011; 339: 99–105.
70. FriedmanJH.Melperone is ineffective in treating Parkinson's disease psychosis. Mov Disord 2012; 27: 803–4.
71. BurnD, EmreM, McKeithI, et al. Effects of rivastigmine in patients with and without visual hallucina- tions in dementia associated with Parkinson's disease. Mov Disord 2006; 21: 1899–907.
72. McKeithI, Del SerT, SpanoPF, et al. Efficacy of rivastigmine in dementia of Lewy bodies: a randomized, double-blinded, placebo-controlled international study. Lancet 2000; 356: 2031–6.
73. ReadingPJ, LuceAK, McKeithIG.Rivastigmine in the treatment of Parkinsonian psychosis and cognitive impairment: preliminary finding from an open trial. Mov Disord 2001; 16: 1171–4.
74. BergmanJ, LernerV.Successful use of donepezil for the treatment of the psychotic symptoms in patients with Parkinson's disease. Clin Neuropharmacol 2002; 25: 107–10.
75. RavinaB, PuttM, SiderowfA, et al. Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 2005; 76: 934–9.
76. AarslandD, LaakeK, LarsenJ, et al. Donepezil for cognitive impairment in Parkinson's disease: a randomized controlled study. J Neurol Neurosurg Psychiatry 2002, 72: 708–12.
77. AarslandD, HutchinsonM, LarsenJP.Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. Int J Geriatr Psychiatry 2003; 18: 937–41.
78. LitvinenkoIV, OdinakMM, Mogil'nayaVI, EmelinAY.Efficacy and safety of galantamine for dementia in patients with Parkinson's disease (an open controlled trial). Neurosci Behav Physiol 2008; 38: 937–45.
79. SleeperRB.Antipsychotic dose-sparing effect with addition of memantine. Ann Pharmacother 2005; 39: 1573–6.
80. RidhaBH, JosephsKA, RoosorMN.Delusions and hallucinations in dementia with Lewy bodies: worsening with memantine. Neurology 2005; 65: 481–2.
81. ZoldanJ, FriedbergG, LivnehM, MelamedE.Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology 1995; 45: 1305–8.
82. VoonV, LangAE.Antidepressants in the treatment of psychosis with comorbid depression in Parkinson disease. Clin Neuropharmacol 2004; 27: 90–2.
83. MecoG, BernardiS.Antidepressant use in treatment of psychosis with comorbid depression in Parkinson's disease. Prof Neuropsychopharmacol Biol Psychiatry 2007; 31: 311–13.
84. CapaldiVF, CarrRB.Citalopram-induced hallucinations and delusions in a young adult. Gen Hosp Psychiatry 2010; 32: 648.e1–3.
85. DiederichNJ, PieriV, GoetzCG.Coping strategies for visual hallucinations in Parkinson's disease. Mov Disord 2003; 18: 831–8.
86. HurwitzTA, CalneDB, WatermanK.Treatment of dopaminomimetic psychosis in Parkinson's disease with electroconvulsive therapy. Can J Neurol Sci 1988; 15: 32–4.
87. FactorSA, MolhoES, BrownDL.Combined clozapine and electroconvulsive therapy for the treatment of drug-induced psychosis in Parkinson's disease. J Neuropsychiatry Clin Neurosci 1995; 7: 304–7.
88. VesperJ, HaakS, OstertagC, NikkhahG.Subthalamic nucleus deep brain stimulation in elderly patients: analysis of outcome and complications. BMC Neurol 2007; 7: 7.
89. ZahodneLB, FernandezHH.Pathophysiology and treatment of psychosis in Parkinson's disease: a review. Drugs Aging 2008; 25: 665–82.
90. FernandezHH, TrieschmannME, OkunMS.Rebound psychosis: effect of discontinuation of antipsychotics in Parkinson's disease. Mov Disord 2005; 20: 104–5.
91. ChouKL, FernandezHH.Combating psychosis in Parkinson's disease patients: the use of antipsychotic drugs. Expert Opin Investig Drugs 2006; 15: 339–49.
92. GoetzCG, StebbinsGT.Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology 1995; 45: 669–71.